Report cover image

Human Microbiome-based Drugs and Diagnostics: Global Markets

Publisher BCC Research
Published May 23, 2025
Length 116 Pages
SKU # WA20050984

Description

Report Scope

The report analyzes the global market for human microbiome-based drugs and diagnostics and market trends. It includes global revenues for the base year 2024, estimated data for 2025 and the compound annual growth rates (CAGRs) for forecast period of 2025 to 2030. The market is segmented by type, application, end user and region. The microbiome-based drug segment is further segmented by route of administration: oral or rectal. Microbiome-based diagnostics are segmented based on product type into instruments, and reagents and kits. End-user segments include hospitals and clinics, pharmaceutical companies and research institutes. Applications include metabolic, gastrointestinal (GI) and infectious diseases, cancer and others. The regions covered include North America, Europe, Asia-Pacific, South America and the Middle East and Africa (MEA). The report discusses emerging technologies and analyzes the competitive landscape, providing the ranking/market shares of leading companies in the market. It also includes a chapter on environmental, social and corporate governance (ESG) developments.

Human microbiome-based products that are intended for wellness or as dietary supplements are outside the scope of the report, as are nonstandardized fecal microbiota transplantation (FMT) procedures. Microbiome-based diagnostics include only products that claim to detect or screen for any disease or condition.

Report Includes
  • 55 data tables and 51 additional tables
  • Analyses of the trends in global markets for human microbiome-based drugs and diagnostics, with revenue data from 2022 to 2024, estimates for 2025, and projected CAGRs through 2030
  • Estimates of the size and revenue prospects for the global market, along with a market share analysis by type, drug route of administration, diagnostics product type, application, end user, and region
  • Facts and figures pertaining to market dynamics, opportunities and deterrents, technological advances, regulations, and the impacts of macroeconomic variables
  • Review of the prevalence of infectious diseases, metabolic disorders and chronic ailments
  • An assessment of current products, clinical trials and identification of new potential markets for novel products and assay development
  • Overview of the sustainability trends and ESG developments in the industry, with emphasis on the ESG practices followed by leading companies, their ESG ratings, and consumer attitudes
  • An analysis of the key patent grants and recently published patents
  • Analysis of the industry structure and value chain, and the competitive landscape, including companies’ market shares, strategic alliances, M&A activity, venture fundings and investment outlook
  • Profiles of the leading companies, including Ferring Pharmaceuticals, Nestlé Health Science, BiomeBank, Genetic Analysis AS, and Vedanta Biosciences Inc.


Companies Mentioned

Biomebank
Enterobiotix Ltd.
Enterome
Ferring
Genetic Analysis
Illumina Inc.
Microbiome Insights
Microbiotica
Nestle Health Science
Oxford Nanopore Technologies Plc
Pacbio
Sfa Therapeutics Inc.
Thermo Fisher Scientific Inc.
Vedanta Biosciences Inc.

Table of Contents

116 Pages
Chapter 1 Executive Summary
Market Outlook
Scope Of Report
Market Summary
Market Dynamics
Emerging Technologies
Analysis By Segment
Regional Analysis
Conclusion
Chapter 2 Market Overview
Overview And Market Definition
Different Microbiomes In Humans
Microbiome, Human Health And Disease
Technologies Aiding Microbiome Research
Culturing And Cultivation
Strategies For The Development Of Microbiome Therapeutics
Additive Microbiome Therapy
Modulatory Microbiome Therapy
Analysis Of Macroeconomic Factors
Geopolitical Factors
Inflation And Currency Exchange Fluctuations
Porter's Five Forces Analysis
Chapter 3 Market Dynamics
Takeaways
Market Drivers
Growing Evidence Of Microbiome-disease Correlation
Microbiome-based Diagnostics For Disease Prevention And Monitoring
Market Restraints
Challenges In Clinical Trial Design
Lack Of Established Regulatory Frameworks
High Costs Of Microbiome Therapeutics
Market Opportunities
Direct-to-consumer Microbiome Testing
Drugs And Diagnostics For Lung And Skin Microbiomes
Chapter 4 Regulatory Landscape
Regulatory Aspects
North America
Europe
Asia-pacific
Chapter 5 Emerging Technologies
Takeaways
Emerging Technologies
Microbial Ecosystem Therapeutics
Metatranscriptome Sequencing
Genetically Modified Microbiome Therapeutics
Combination And Adjuvant Therapies With Microbiome-based Drugs
Novel Preclinical Models
Chapter 6 Market Segmentation Analysis
Segmentation Breakdown
Market Analysis By Type
Microbiome-based Drugs
Market Analysis By Application
Infectious Diseases
Gi Disorders
Metabolic Disorders
Cancer
Other Diseases
Market Analysis By End User
Hospitals And Clinics
Research Institutions
Pharmaceutical Companies
Geographic Breakdown
Market Analysis By Region
North America
Europe
Asia-pacific
South America
Middle East And Africa
Chapter 7 Competitive Intelligence
Takeaways
Company Share Analysis
Competitive Analysis
Venture Funding And Investment Landscape
Recent Developments
Chapter 8 Sustainability In The Human Microbiome-based Drugs And Diagnostics Industry: An Esg Perspective
Introduction To Esg
Esg Risk Ratings
Concluding Remarks
Chapter 9 Appendix
Methodology
Sources
Abbreviations
Company Profiles
Biomebank
Enterobiotix Ltd.
Enterome
Ferring
Genetic Analysis
Illumina Inc.
Microbiome Insights
Microbiotica
Nestle Health Science
Oxford Nanopore Technologies Plc
Pacbio
Sfa Therapeutics Inc.
Thermo Fisher Scientific Inc.
Vedanta Biosciences Inc.
Emerging Start-ups/Market Disruptors

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us